Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy

Objectives:This study investigated the development of insulin resistance (IR) secondary to the use of valproic acid (VPA) and carbamazepine (CBZ), which are highly effective and frequently used antiepileptic drugs.Methods:This cross-sectional prospective cohort study included 111 participants aged 1...

Full description

Saved in:
Bibliographic Details
Published in:Archives of Epilepsy 2016-12, Vol.22 (3), p.102-107
Main Authors: Selda KESKİN GÜLER, Nalan GÜNEŞ, Burcu Gökçe ÇOKAL, Tahir YOLDAŞ, Elif Banu SÖKER
Format: Article
Language:English
Subjects:
c-peptide
carbamazepine
insulin resistance
valproic acid
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 107
container_issue 3
container_start_page 102
container_title Archives of Epilepsy
container_volume 22
creator Selda KESKİN GÜLER
Nalan GÜNEŞ
Burcu Gökçe ÇOKAL
Tahir YOLDAŞ
Elif Banu SÖKER
description Objectives:This study investigated the development of insulin resistance (IR) secondary to the use of valproic acid (VPA) and carbamazepine (CBZ), which are highly effective and frequently used antiepileptic drugs.Methods:This cross-sectional prospective cohort study included 111 participants aged 15 to 64 years. Patients diagnosed with epilepsy were divided into 2 groups: those using VPA (n=45) and those using CBZ (n=35). Those groups were compared to healthy control group (n=31). Preprandial blood glucose, insulin, C-peptide levels were examined, and IR was calculated. Anthropometric measurements were taken.Results:A significant relationship was identified between VPA or CBZ use and development of IR (p
doi_str_mv 10.5505/epilepsi.2016.88700
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b898</doaj_id><sourcerecordid>oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b898</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b8983</originalsourceid><addsrcrecordid>eNqtjs9KAzEYxIMgWLRP4CUv0DWb7p_k3FbsQRARr-Hb7LdtlmwSklRZn95FfQRPwww_ZoaQ-5IVdc3qBwzGYkim4KxsCiFaxq7IireSb9gC3JB1SiNjjEu-bUu5IuMeP9D6MKHL1A_06NLFGkdfMZmUwWmki3uBbBYg0U-Tz_TwOzLT_SUad6LvYEP0kJGC6-kOYgcTfC1XHNJn73w-Y4Qw35HrAWzC9Z_ekuPj4W33tOk9jCpEM0GclQejfgIfTwpiNtqiahvNQVS91Bor3vRQVR2XQy24Zp2QYvufXd-4Imq1</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy</title><source>DOAJ Directory of Open Access Journals</source><creator>Selda KESKİN GÜLER ; Nalan GÜNEŞ ; Burcu Gökçe ÇOKAL ; Tahir YOLDAŞ ; Elif Banu SÖKER</creator><creatorcontrib>Selda KESKİN GÜLER ; Nalan GÜNEŞ ; Burcu Gökçe ÇOKAL ; Tahir YOLDAŞ ; Elif Banu SÖKER</creatorcontrib><description>Objectives:This study investigated the development of insulin resistance (IR) secondary to the use of valproic acid (VPA) and carbamazepine (CBZ), which are highly effective and frequently used antiepileptic drugs.Methods:This cross-sectional prospective cohort study included 111 participants aged 15 to 64 years. Patients diagnosed with epilepsy were divided into 2 groups: those using VPA (n=45) and those using CBZ (n=35). Those groups were compared to healthy control group (n=31). Preprandial blood glucose, insulin, C-peptide levels were examined, and IR was calculated. Anthropometric measurements were taken.Results:A significant relationship was identified between VPA or CBZ use and development of IR (p&lt;0.05). C-peptide level was significantly higher in patients who used antiepileptic drugs than in control group (p&lt;0.05). Average body mass index (BMI) was not different between groups.Conclusion:In patients under antiepileptic treatment, neuroendocrine dysfunction, such as insulin metabolism disorders, can develop in addition to common side effects. Thus, symptoms should be followed up carefully and patients should be evaluated in terms of side effects both before starting and during treatment.</description><identifier>EISSN: 2792-0550</identifier><identifier>DOI: 10.5505/epilepsi.2016.88700</identifier><language>eng</language><publisher>Galenos Yayinevi</publisher><subject>c-peptide ; carbamazepine ; insulin resistance ; valproic acid</subject><ispartof>Archives of Epilepsy, 2016-12, Vol.22 (3), p.102-107</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,2102,27924,27925</link.rule.ids></links><search><creatorcontrib>Selda KESKİN GÜLER</creatorcontrib><creatorcontrib>Nalan GÜNEŞ</creatorcontrib><creatorcontrib>Burcu Gökçe ÇOKAL</creatorcontrib><creatorcontrib>Tahir YOLDAŞ</creatorcontrib><creatorcontrib>Elif Banu SÖKER</creatorcontrib><title>Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy</title><title>Archives of Epilepsy</title><description>Objectives:This study investigated the development of insulin resistance (IR) secondary to the use of valproic acid (VPA) and carbamazepine (CBZ), which are highly effective and frequently used antiepileptic drugs.Methods:This cross-sectional prospective cohort study included 111 participants aged 15 to 64 years. Patients diagnosed with epilepsy were divided into 2 groups: those using VPA (n=45) and those using CBZ (n=35). Those groups were compared to healthy control group (n=31). Preprandial blood glucose, insulin, C-peptide levels were examined, and IR was calculated. Anthropometric measurements were taken.Results:A significant relationship was identified between VPA or CBZ use and development of IR (p&lt;0.05). C-peptide level was significantly higher in patients who used antiepileptic drugs than in control group (p&lt;0.05). Average body mass index (BMI) was not different between groups.Conclusion:In patients under antiepileptic treatment, neuroendocrine dysfunction, such as insulin metabolism disorders, can develop in addition to common side effects. Thus, symptoms should be followed up carefully and patients should be evaluated in terms of side effects both before starting and during treatment.</description><subject>c-peptide</subject><subject>carbamazepine</subject><subject>insulin resistance</subject><subject>valproic acid</subject><issn>2792-0550</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjs9KAzEYxIMgWLRP4CUv0DWb7p_k3FbsQRARr-Hb7LdtlmwSklRZn95FfQRPwww_ZoaQ-5IVdc3qBwzGYkim4KxsCiFaxq7IireSb9gC3JB1SiNjjEu-bUu5IuMeP9D6MKHL1A_06NLFGkdfMZmUwWmki3uBbBYg0U-Tz_TwOzLT_SUad6LvYEP0kJGC6-kOYgcTfC1XHNJn73w-Y4Qw35HrAWzC9Z_ekuPj4W33tOk9jCpEM0GclQejfgIfTwpiNtqiahvNQVS91Bor3vRQVR2XQy24Zp2QYvufXd-4Imq1</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Selda KESKİN GÜLER</creator><creator>Nalan GÜNEŞ</creator><creator>Burcu Gökçe ÇOKAL</creator><creator>Tahir YOLDAŞ</creator><creator>Elif Banu SÖKER</creator><general>Galenos Yayinevi</general><scope>DOA</scope></search><sort><creationdate>20161201</creationdate><title>Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy</title><author>Selda KESKİN GÜLER ; Nalan GÜNEŞ ; Burcu Gökçe ÇOKAL ; Tahir YOLDAŞ ; Elif Banu SÖKER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b8983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>c-peptide</topic><topic>carbamazepine</topic><topic>insulin resistance</topic><topic>valproic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Selda KESKİN GÜLER</creatorcontrib><creatorcontrib>Nalan GÜNEŞ</creatorcontrib><creatorcontrib>Burcu Gökçe ÇOKAL</creatorcontrib><creatorcontrib>Tahir YOLDAŞ</creatorcontrib><creatorcontrib>Elif Banu SÖKER</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Archives of Epilepsy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Selda KESKİN GÜLER</au><au>Nalan GÜNEŞ</au><au>Burcu Gökçe ÇOKAL</au><au>Tahir YOLDAŞ</au><au>Elif Banu SÖKER</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy</atitle><jtitle>Archives of Epilepsy</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>22</volume><issue>3</issue><spage>102</spage><epage>107</epage><pages>102-107</pages><eissn>2792-0550</eissn><abstract>Objectives:This study investigated the development of insulin resistance (IR) secondary to the use of valproic acid (VPA) and carbamazepine (CBZ), which are highly effective and frequently used antiepileptic drugs.Methods:This cross-sectional prospective cohort study included 111 participants aged 15 to 64 years. Patients diagnosed with epilepsy were divided into 2 groups: those using VPA (n=45) and those using CBZ (n=35). Those groups were compared to healthy control group (n=31). Preprandial blood glucose, insulin, C-peptide levels were examined, and IR was calculated. Anthropometric measurements were taken.Results:A significant relationship was identified between VPA or CBZ use and development of IR (p&lt;0.05). C-peptide level was significantly higher in patients who used antiepileptic drugs than in control group (p&lt;0.05). Average body mass index (BMI) was not different between groups.Conclusion:In patients under antiepileptic treatment, neuroendocrine dysfunction, such as insulin metabolism disorders, can develop in addition to common side effects. Thus, symptoms should be followed up carefully and patients should be evaluated in terms of side effects both before starting and during treatment.</abstract><pub>Galenos Yayinevi</pub><doi>10.5505/epilepsi.2016.88700</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2792-0550
ispartof Archives of Epilepsy, 2016-12, Vol.22 (3), p.102-107
issn 2792-0550
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b898
source DOAJ Directory of Open Access Journals
subjects c-peptide
carbamazepine
insulin resistance
valproic acid
title Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A05%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Insulin%20Resistance%20in%20Patients%20with%20Epilepsy%20During%20Valproate%20and%20Carbamazepine%20Monotherapy&rft.jtitle=Archives%20of%20Epilepsy&rft.au=Selda%20KESK%C4%B0N%20G%C3%9CLER&rft.date=2016-12-01&rft.volume=22&rft.issue=3&rft.spage=102&rft.epage=107&rft.pages=102-107&rft.eissn=2792-0550&rft_id=info:doi/10.5505/epilepsi.2016.88700&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_76c2a84d9cce426da44b29f582c0b898%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_76c2a84d9cce426da44b29f582c0b8983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true